Scholarlink

Background <p>HLA-B27 is strongly associated with axial spondyloarthritis (axSpA) and influences disease phenotype, though its prevalence and clinical relevance vary by population. Magnetic resonance imaging (MRI)-based cohorts offer substantial information about early axSpA detection and phenotype expression. Data from Saudi Arabia remain limited.</p> Objective <p>To compare clinical characteristics, diagnostic delay, inflammatory markers, MRI findings, and treatment patterns between HLA-B27-positive and HLA-B27-negative patients with MRI-confirmed axial spondyloarthritis.</p> Methods <p>This retrospective cross-sectional study included adults with clinician-diagnosed axSpA fulfilling ASAS imaging criteria. Clinical features, C-reactive protein (CRP) levels, MRI findings, and treatment utilization were compared between HLA-B27 groups. Diagnostic delay was analyzed as continuous and categorical data.</p> Results <p>Eighty-four patients were included (32 HLA-B27 positive; 52 HLA-B27 negative). HLA-B27 positive patients were more frequently male (<i>p</i> = 0.004) and had higher rates of uveitis (<i>p</i> = 0.006), family history of SpA (<i>p</i> &lt; 0.001), and elevated CRP levels (<i>p</i> &lt; 0.001). Diagnostic delay was prolonged in both groups. Median diagnostic delay did not differ significantly between groups (<i>p</i> = 0.48). Spinal inflammatory involvement on MRI was more frequent in HLA-B27 positive patients but did not reach statistical significance (<i>p</i> = 0.11). No significant differences in biologic treatment utilization were observed.</p> Conclusion <p>In this MRI-confirmed axial spondyloarthritis cohort, HLA-B27 positive patients exhibited a more defined axial and extra-musculoskeletal phenotype with higher systemic inflammation. Peripheral manifestations, diagnostic delay, and biologic treatment patterns were broadly comparable between HLA-B27 subgroups. These findings highlight regional phenotype variation and support the continued role of MRI-based evaluation in axSpA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical phenotype, MRI inflammatory involvement, and treatment patterns in HLA-B27 positive and negative axial spondyloarthritis: a Saudi MRI-based cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月18日

查看全文
  • Abdallah Alqethami,
  • Mohammed Basalama,
  • Samiyah Alsaedi,
  • Khulud Alqahtani,
  • Eman Alsindi,
  • Sabri Alsaeedi,
  • Roaa Mahroos,
  • Maysoon Taher

摘要

Background

HLA-B27 is strongly associated with axial spondyloarthritis (axSpA) and influences disease phenotype, though its prevalence and clinical relevance vary by population. Magnetic resonance imaging (MRI)-based cohorts offer substantial information about early axSpA detection and phenotype expression. Data from Saudi Arabia remain limited.

Objective

To compare clinical characteristics, diagnostic delay, inflammatory markers, MRI findings, and treatment patterns between HLA-B27-positive and HLA-B27-negative patients with MRI-confirmed axial spondyloarthritis.

Methods

This retrospective cross-sectional study included adults with clinician-diagnosed axSpA fulfilling ASAS imaging criteria. Clinical features, C-reactive protein (CRP) levels, MRI findings, and treatment utilization were compared between HLA-B27 groups. Diagnostic delay was analyzed as continuous and categorical data.

Results

Eighty-four patients were included (32 HLA-B27 positive; 52 HLA-B27 negative). HLA-B27 positive patients were more frequently male (p = 0.004) and had higher rates of uveitis (p = 0.006), family history of SpA (p < 0.001), and elevated CRP levels (p < 0.001). Diagnostic delay was prolonged in both groups. Median diagnostic delay did not differ significantly between groups (p = 0.48). Spinal inflammatory involvement on MRI was more frequent in HLA-B27 positive patients but did not reach statistical significance (p = 0.11). No significant differences in biologic treatment utilization were observed.

Conclusion

In this MRI-confirmed axial spondyloarthritis cohort, HLA-B27 positive patients exhibited a more defined axial and extra-musculoskeletal phenotype with higher systemic inflammation. Peripheral manifestations, diagnostic delay, and biologic treatment patterns were broadly comparable between HLA-B27 subgroups. These findings highlight regional phenotype variation and support the continued role of MRI-based evaluation in axSpA.